ArticleMolecular cancer therapeutics2026

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

Jianhui Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.